biotech / news / / The Manila Times
For patients whose time to progression on immediate prior therapy was >18 months, median progression-free survival was 12.4 months with gedatolisib + palbociclib + fulvestrant.
Gedatolisib triplet showed a median PFS of 16.6 months in US, Canada, Western Europe, and Asia Pacific.
KEY POINTS
- Patients progressing >18 months on prior therapy had median PFS of 12.4 months with gedatolisib triplet.
- No clinically relevant hyperglycemia or dose reductions due to hyperglycemia were reported with gedatolisib.
- Stomatitis from gedatolisib was generally controlled, resolving to a lower grade within two weeks.
COMPANIES
Summarized by Newsio from The Manila Times. How we summarize →